Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.49040
Abstract: Key Points Question Does targeting programmed cell death 1 or programmed cell death ligand 1 enhance the clinical benefits of anti–vascular endothelial growth factor therapy in patients with refractory metastatic colorectal cancer (mCRC)? Findings In… read more here.
Keywords: programmed cell; capecitabine bevacizumab; cell death; capecitabine ... See more keywords
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2016.6120
Abstract: Importance Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and… read more here.
Keywords: early breast; capecitabine; docetaxel epirubicin; breast cancer ... See more keywords
Pharmacokinetics and Comparative Bioavailability of Test or Reference Capecitabine and Discrepant Pharmacokinetics Among Various Tumors in Chinese Solid Cancer Patients
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1202
Abstract: The main objective of this study was to compare the pharmacokinetic (PK) bioequivalence of two capecitabine tablets and explore the different PK profiles of various tumors in Chinese patients with cancer. All 76 patients with… read more here.
Keywords: capecitabine; test reference; reference; reference capecitabine ... See more keywords
Clinical evidence of prevention strategies for capecitabine‐induced hand‐foot syndrome
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Cancer"
DOI: 10.1002/ijc.31269
Abstract: Hand‐foot syndrome (HFS) is the most common adverse effect of capecitabine‐containing chemotherapy. The purpose of this study was to assess the efficacies of various prevention and treatment strategies for capecitabine‐induced HFS. Searches of the PubMed… read more here.
Keywords: foot syndrome; capecitabine; induced hfs; strategies capecitabine ... See more keywords
A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3458-7
Abstract: PurposeThe addition of cetuximab to triplet chemotherapy can increase treatment efficacy for patients with metastatic colorectal cancer (mCRC). We explored the dose-limiting toxicity and feasibility of a triweekly capecitabine, oxaliplatin, irinotecan, plus cetuximab (XELOXIRI plus… read more here.
Keywords: cetuximab; capecitabine; plus cetuximab; cancer ... See more keywords
Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03837-y
Abstract: PurposeSeveral retrospective studies have shown that the antitumor efficacy of capecitabine-containing chemotherapy decreases when co-administered with a proton pump inhibitor (PPI). Although a reduction in capecitabine absorption by PPIs was proposed as the underlying mechanism,… read more here.
Keywords: deoxy fluorouridine; capecitabine; fluorocytidine deoxy; rabeprazole intake ... See more keywords
Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-020-04208-8
Abstract: Purpose The present study was performed to examine relationships between systemic exposure of capecitabine metabolites (5-FU, 5′-DFCR and 5′-DFUR) and toxicity or clinical response in patients with metastatic breast cancer. Methods A population pharmacokinetic model… read more here.
Keywords: population pharmacokinetic; capecitabine; breast cancer; toxicity ... See more keywords
Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study
Sign Up to like & getrecommendations! Published in 2021 at "Investigational New Drugs"
DOI: 10.1007/s10637-021-01125-2
Abstract: Background FOLFOXIRI plus bevacizumab is the first-line treatment for metastatic colorectal cancer (mCRC) but demonstrates high neutropenia incidence among Asian patients. Hence, we conducted the randomized phase II QUATTRO-II study (ClinicalTrials.gov identifier: NCT04097444; Japan Registry… read more here.
Keywords: first line; safety; capecitabine; bevacizumab first ... See more keywords
Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-018-0597-y
Abstract: Opinion statementNowadays, systemic chemotherapy with intravenous (IV) 5-fluorouracil (5-FU) remains the most commonly prescribed treatment for metastatic colorectal cancers (CRC), in combination with other cytotoxic drugs. 5-FU can be administered through a bolus injection or… read more here.
Keywords: metastatic colorectal; continuous infusion; treatment; capecitabine ... See more keywords
[Evaluation of the practice of prescribing oral chemotherapy type "Capecitabine" by medical oncologist: A first study from Morocco].
Sign Up to like & getrecommendations! Published in 2021 at "Bulletin du cancer"
DOI: 10.1016/j.bulcan.2021.04.019
Abstract: INTRODUCTION Oral anticancer therapy is becoming increasingly developed; their prescription has become a common practice in oncology. However, there is a variability and diversity in prescription practice. Its magnitude has been very little studied in… read more here.
Keywords: chemotherapy; capecitabine; practice; prescription ... See more keywords
Phase I Trial of Everolimus and Capecitabine in Metastatic HER2- Breast Cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Clinical breast cancer"
DOI: 10.1016/j.clbc.2017.03.003
Abstract: BACKGROUND The mammalian target of rapamycin (mTOR) pathway is a driver of breast tumorigenesis. The mTOR inhibitor everolimus reverses antihormonal therapy resistance and is an approved therapy for metastatic breast cancer. A synergistic effect with… read more here.
Keywords: everolimus capecitabine; capecitabine; breast; breast cancer ... See more keywords